Search

Lijun Dr Wu

from Berkeley, CA
Age ~63
Get Report
Also known as:
Lijun J Wu, John Wu, Li Wu, Jun Wu Li, Li Junwu, Wu Li
Phone and address:
715 Johnson St, Berkeley, CA 94706
(510) 526-1251
Related to:
Daisy Tian Xin Wu, 56Chun Li, 63Li Yan, 63Bao F Qi, 62Yixin Liu, 58
Connected to:
Agna J Wu, 42Al Y Wu, 87Alena C Wu, 55Alis W Wu, 35Altaira R Wu, 52Amanda B Wu, 42Amy Wu, 51Anastasia M Wu, 46Andi Wu, 35Andria J Wu, 34

Lijun Wu Phones & Addresses

  • 715 Johnson St, Albany, CA 94706 (510) 526-1251
  • Berkeley, CA
  • Oakland, CA
  • San Ramon, CA
  • Richmond, CA
  • San Francisco, CA
  • 715 Johnson St, Albany, CA 94706

Work

Position: Clerical/White Collar

Education

Degree: Associate degree or higher

Business Records

Name / Title
Company / Classification
Phones & Addresses
Lijun Wu
President
ProMab Biotechnologies, Inc.
Biotechnology · Distributor Biotechnology Products · Commercial Physical Research
5221 Central Ave SUITE 200, Richmond, CA 94804
715 Johnson St, Berkeley, CA 94706
(510) 860-4615
Lijun Wu
President
AFFINIGEN, INC
1300 Bancroft Ave STE G-1, San Leandro, CA 94577

Publications

Us Patents

Modulation Of Systemic Memory T Cell Trafficking

View page
US Patent:
6881406, Apr 19, 2005
Filed:
Apr 17, 2001
Appl. No.:
09/837446
Inventors:
Eugene C. Butcher - Portola Valley CA, US
James J. Campbell - Palo Alto CA, US
Lijun Wu - Reading MA, US
James B. Rottman - Sudbury MA, US
Assignee:
The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA
Millennium Pharmaceuticals, Inc. - Cambridge MA
International Classification:
A61K039/395
US Classification:
4241301, 4241331, 4241371, 4241411, 4241431, 4241441, 4241521, 4241531, 4241541, 4241841
Abstract:
Methods are provided to specifically modulate the trafficking of systemic memory T cells, particularly CD4+ T cells, without affecting naive T cells or intestinal memory T cells. It is shown that systemic memory T cells, which are characterized as CD45Ra, and integrin α4β7, express high levels of CCR4. Ligands of CCR4, such as TARC or MDC, act as an adhesion trigger, wherein upon CCR4 binding, these cells undergo integrin-dependent arrest to the appropriate vascular receptor(s). This arrest acts to localize the cells at the target site. The methods of the invention manipulate this triggering, and CCR4 mediated chemotaxis, to affect the localization of T cells in targeted tissues. In an alternative embodiment, the agent is an antagonist that blocks CCR4 biological activity. An advantage of the invention is the selectivity for systemic memory T cells, without affecting native T cells or intestinal memory T cells.

Modulation Of Systemic Memory T Cell Trafficking

View page
US Patent:
20050169918, Aug 4, 2005
Filed:
Feb 17, 2005
Appl. No.:
11/061052
Inventors:
Eugene Butcher - Portola Valley CA, US
James Campbell - Weymouth MA, US
Lijun Wu - Lexington MA, US
James Rottman - Sudbury MA, US
International Classification:
G01N033/567
A61K039/395
US Classification:
424143100, 435007210
Abstract:
Methods are provided to specifically modulate the trafficking of systemic memory T cells, particularly CD4+ T cells, without affecting naive T cells or intestinal memory T cells. It is shown that systemic memory T cells, which are characterized as CD45Ra, and integrin α4β7, express high levels of CCR4. Ligands of CCR4, such as TARC or MDC, act as an adhesion trigger, wherein upon CCR4 binding, these cells undergo integrin-dependent arrest to the appropriate vascular receptor(s). This arrest acts to localize the cells at the target site. The methods of the invention manipulate this triggering, and CCR4 mediated chemotaxis, to affect the localization of T cells in targeted tissues. In one embodiment of the invention, the active agent is a CCR4 agonist, that acts to enhance T cell localization. In an alternative embodiment, the agent is an antagonist that blocks CCR4 biological activity. An advantage of the invention is the selectivity for systemic memory T cells, without affecting native T cells or intestinal memory T cells.

Modulation Of Systemic Memory T Cell Trafficking

View page
US Patent:
62453327, Jun 12, 2001
Filed:
Jan 15, 1999
Appl. No.:
9/232878
Inventors:
Eugene C. Butcher - Portola Valley CA
James J. Campbell - Palo Alto CA
Lijun Wu - Reading MA
James B. Rottman - Sudbury MA
Assignee:
The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA
LeukoSite, Inc. - Cambridge MA
International Classification:
A61K 3938
A61K 39395
A61K 3800
A61K 4500
G01N 3353
US Classification:
4241841
Abstract:
Methods are provided to specifically modulate the trafficking of systemic memory T cells, particularly CD4+ T cells, without affecting naive T cells or intestinal memory T cells. It is shown that systemic memory T cells, which are characterized as CD45Ra. sup. -, and integrin. alpha. 4. beta. 7. sup. -, express high levels of CCR4. Ligands of CCR4, such as TARC or MDC, act as an adhesion trigger, wherein upon CCR4 binding, these cells undergo integrin-dependent arrest to the appropriate vascular receptor(s). This arrest acts to localize the cells at the target site. The methods of the invention manipulate this triggering, and CCR4 mediated chemotaxis, to affect the localization of T cells in targeted tissues. In one embodiment of the invention, the active agent is a CCR4 agonist, that acts to enhance T cell localization. In an alternative embodiment, the agent is an antagonist that blocks CCR4 biological activity.

Humanized Bcma-Car-T Cells

View page
US Patent:
20200190163, Jun 18, 2020
Filed:
Oct 25, 2019
Appl. No.:
16/664789
Inventors:
Lijun Wu - Albany CA, US
Vita Golubovskaya - Pinole CA, US
Effie Ho - Green Brook NJ, US
International Classification:
C07K 14/715
Abstract:
The present invention is directed to a humanized BCMA single-chain variable fragment (scFv), comprising Vhaving the amino acid sequence of SEQ ID NO: 7 and Vhaving the amino acid sequence of SEQ ID NO: 8. The present invention is also directed to a BCMA chimeric antigen receptor fusion protein comprising from N-terminus to C-terminus: (i) a single-chain variable fragment (scFv) of the present invention, (ii) a transmembrane domain, (iii) at least one co-stimulatory domains, and (iv) an activating domain. This humanized BCMA-CAR-T cells have specific killing activity with secretion of cytokine IFN-γ in CAR-T cells in vitro and in vivo.

Adherent Cancer Cell Line Expressing A Hematological Tumor Antigen

View page
US Patent:
20190015493, Jan 17, 2019
Filed:
Oct 1, 2018
Appl. No.:
16/148974
Inventors:
- Richmond CA, US
- Changsha, CN
Lijun Wu - Albany CA, US
International Classification:
A61K 39/00
C12N 5/09
C12N 15/09
C07K 14/47
C07K 14/705
C07K 16/28
G01N 33/49
C12N 5/071
C12N 15/85
Abstract:
The present invention relates to a transduced cancer cell line stably expressing a leukemia tumor antigen, wherein the cancer cell line is cervical cancer cells, breast cancer cells, ovarian cancer cells, pancreatic cancer cells, lung cancer cells, or glioblastoma cells. The transduced adherent cell line of the present invention is useful for many pre-clinical applications such as real time cytotoxicity assay or to test the effects of CAR-T cells that target the tumor antigen. The present invention is exemplified by Hela cell line stably expressing CD19.

Adherent Cancer Cell Line Expressing A Hematological Tumor Antigen

View page
US Patent:
20170348403, Dec 7, 2017
Filed:
May 31, 2017
Appl. No.:
15/610419
Inventors:
- Richmond CA, US
- Changsha, CN
Lijun WU - Albany CA, US
International Classification:
A61K 39/00
C07K 14/47
C12N 15/09
G01N 33/49
C12N 5/071
C12N 15/85
Abstract:
The present invention relates to a transduced cancer cell line stably expressing a leukemia tumor antigen, wherein the cancer cell line is cervical cancer cells, breast cancer cells, ovarian cancer cells, pancreatic cancer cells, lung cancer cells, or glioblastoma cells. The transduced adherent cell line of the present invention is useful for many pre-clinical applications such as real time cytotoxicity assay or to test the effects of CAR-T cells that target the tumor antigen. The present invention is exemplified by Hela cell line stably expressing CD19.

Cassette Attachment Device For Detecting Intensity Of Test Strip Cassette

View page
US Patent:
20160381265, Dec 29, 2016
Filed:
Jun 24, 2016
Appl. No.:
15/192963
Inventors:
- Richmond CA, US
Lijun WU - Albany CA, US
International Classification:
H04N 5/225
H04W 4/00
Abstract:
Techniques for fast and accurate measuring test strip intensities are disclosed herein. A cassette attachment device for detecting intensity of a test strip cassette includes a strip chamber configured to accommodate at least a portion of a test strip, a light source configured to provide illumination to the test strip cassette via indirect lighting, an attaching mechanism configured to attach the device to a mobile device, and a camera window configured to transmit light signal reflected from the test strip cassette such that the mobile device can capture an image of the test strip cassette illuminated by the light source.

Systems And Methods For Fast Test Strip Intensity Recognition

View page
US Patent:
20140219885, Aug 7, 2014
Filed:
Jan 30, 2014
Appl. No.:
14/169066
Inventors:
Ge Cong - Pleasanton CA, US
Lijun Wu - Pleasanton CA, US
Richard Cong - Pleasanton CA, US
International Classification:
G01N 21/17
G06T 7/00
G01N 33/558
US Classification:
422403, 382128
Abstract:
Techniques for fast and accurate measuring test strip intensities are disclosed herein. A method for measuring a test strip intensity comprising steps of obtaining an image of a sample line in a test strip and a plurality of reference lines, wherein the reference lines have known intensities; determining grayscale values of the sample line and the reference lines from the image; constructing a standard curve based on the grayscale values versus the known intensities of the reference lines; and determining the intensity of the sample line by fitting the grayscale value of the sample line on the standard curve.
Control profile
Lijun Dr Wu from Berkeley, CA, age ~63 Get Report